Background FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combination with cetuximab or panitumumab, respectively, achieved high therapeutic activity in RAS and BRAF wild-type patients with an acceptable toxicity profile. Drawing from these considerations, we designed TRIPLETE study aiming at comparing two different chemotherapy backbones (mFOLFOXIRI or mFOLFOX6) in combination with panitumumab in the first-line treatment of patients with RAS and BRAF wild-type metastatic colorectal cancer.Methods This is a prospective, open-label, multicentre phase III trial in which initially unresectable and previously untreated RAS and BRAF wild-type metastatic colorectal cancer patients are randomised to receive a standard treatment with mFOLFOX6 plus panitumumab or an experimental regimen with modified FOLFOXIRI (irinotecan 150 mg/m(2), oxaliplatin 85 mg/m(2), L-leucovorin 200 mg/m(2), 5-fluoruracil 2400 mg/m2 48-hour continuous infusion) plus panitumumab up to 12 cycles, followed by panitumumab plus 5-fluorouracil and L-leucovorin until disease progression. The primary endpoint is overall response rate according to RECIST 1.1 criteria.Discussion The relative benefit of chemotherapy intensification when using an anti-EGFR-based regimen in molecularly selected patients is unknown; TRIPLETE study aims at filling this gap of knowledge. The study is sponsored by the Gruppo Oncologico Nord Ovest Cooperative Group and is currently ongoing at 42 Italian centres.

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer / Borelli, Beatrice; Moretto, Roberto; Lonardi, Sara; Bonetti, Andrea; Antoniotti, Carlotta; Pietrantonio, Filippo; Masi, Gianluca; Burgio, Valentina; Marmorino, Federica; Salvatore, Lisa; Rossini, Daniele; Zaniboni, Alberto; Zucchelli, Gemma; Martignetti, Angelo; Di Battista, Monica; Pella, Nicoletta; Passardi, Alessandro; Boccaccino, Alessandra; Leone, Francesco; Colombo, Camilla; Granetto, Cristina; Vannini, Francesca; Marsico, Valentina Angela; Martinelli, Erika; Antonuzzo, Lorenzo; Vitello, Stefano; Delliponti, Laura; Boni, Luca; Cremolini, Chiara; Falcone, Alfredo. - In: ESMO OPEN. - ISSN 2059-7029. - STAMPA. - 3:(2018), pp. 000403.1-000403.8. [10.1136/esmoopen-2018-000403]

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

Masi, Gianluca;Rossini, Daniele;Antonuzzo, Lorenzo;Boni, Luca;
2018

Abstract

Background FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combination with cetuximab or panitumumab, respectively, achieved high therapeutic activity in RAS and BRAF wild-type patients with an acceptable toxicity profile. Drawing from these considerations, we designed TRIPLETE study aiming at comparing two different chemotherapy backbones (mFOLFOXIRI or mFOLFOX6) in combination with panitumumab in the first-line treatment of patients with RAS and BRAF wild-type metastatic colorectal cancer.Methods This is a prospective, open-label, multicentre phase III trial in which initially unresectable and previously untreated RAS and BRAF wild-type metastatic colorectal cancer patients are randomised to receive a standard treatment with mFOLFOX6 plus panitumumab or an experimental regimen with modified FOLFOXIRI (irinotecan 150 mg/m(2), oxaliplatin 85 mg/m(2), L-leucovorin 200 mg/m(2), 5-fluoruracil 2400 mg/m2 48-hour continuous infusion) plus panitumumab up to 12 cycles, followed by panitumumab plus 5-fluorouracil and L-leucovorin until disease progression. The primary endpoint is overall response rate according to RECIST 1.1 criteria.Discussion The relative benefit of chemotherapy intensification when using an anti-EGFR-based regimen in molecularly selected patients is unknown; TRIPLETE study aims at filling this gap of knowledge. The study is sponsored by the Gruppo Oncologico Nord Ovest Cooperative Group and is currently ongoing at 42 Italian centres.
3
1
8
Borelli, Beatrice; Moretto, Roberto; Lonardi, Sara; Bonetti, Andrea; Antoniotti, Carlotta; Pietrantonio, Filippo; Masi, Gianluca; Burgio, Valentina; Marmorino, Federica; Salvatore, Lisa; Rossini, Daniele; Zaniboni, Alberto; Zucchelli, Gemma; Martignetti, Angelo; Di Battista, Monica; Pella, Nicoletta; Passardi, Alessandro; Boccaccino, Alessandra; Leone, Francesco; Colombo, Camilla; Granetto, Cristina; Vannini, Francesca; Marsico, Valentina Angela; Martinelli, Erika; Antonuzzo, Lorenzo; Vitello, Stefano; Delliponti, Laura; Boni, Luca; Cremolini, Chiara; Falcone, Alfredo
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1287152
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 17
social impact